Search

Your search keyword '"Paolini, Stefania"' showing total 1,019 results

Search Constraints

Start Over You searched for: Author "Paolini, Stefania" Remove constraint Author: "Paolini, Stefania" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
1,019 results on '"Paolini, Stefania"'

Search Results

1. Psychological well-being in Europe after the outbreak of war in Ukraine

2. Detection of Cancer Stem Cells in Normal and Dysplastic/Leukemic Human Blood

3. Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial

4. Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial

6. Deciphering signaling pathways in hematopoietic stem cells: the molecular complexity of Myelodysplastic Syndromes (MDS) and leukemic progression

8. A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes

9. 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial

10. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial

12. Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial

13. INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia

15. Preliminary safety and efficacy of oral azacitidine (Oral-AZA) in patients (pts) with low-/Intermediate (Int)-risk myelodysplastic syndromes (MDS): Phase 2 results from the ASTREON trial.

16. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

17. Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients

18. Psychological well-being in Europe after the outbreak of war in Ukraine

19. Reaching across social divides deliberately: Theoretical, political, and practical implications of intergroup contact volition for intergroup relations.

20. Negativity Bias in Intergroup Contact: Meta-Analytical Evidence That Bad Is Stronger Than Good, Especially When People Have the Opportunity and Motivation to Opt Out of Contact.

23. MDS-157 Luspatercept Versus Epoetin Alfa (EA) for Treatment of Anemia in Patients With Erythropoiesis-Stimulating Agent (ESA)-Naive Lower-Risk Myelodysplastic Syndromes (LR-MDS) Requiring Red Blood Cell (RBC) Transfusions: Data from the Phase III COMMANDS Study

24. Oral Abstract: MDS-157 Luspatercept Versus Epoetin Alfa (EA) for Treatment of Anemia in Patients With Erythropoiesis-Stimulating Agent (ESA)-Naive Lower-Risk Myelodysplastic Syndromes (LR-MDS) Requiring Red Blood Cell (RBC) Transfusions: Data from the Phase III COMMANDS Study

25. POSTER: MDS-157 Luspatercept Versus Epoetin Alfa (EA) for Treatment of Anemia in Patients With Erythropoiesis-Stimulating Agent (ESA)-Naive Lower-Risk Myelodysplastic Syndromes (LR-MDS) Requiring Red Blood Cell (RBC) Transfusions: Data from the Phase III COMMANDS Study

26. P558: ABSOLUTE LYMPHOCYTE COUNT IS AN INDEPENDENT SURVIVAL PREDICTOR COMPARED TO MINIMAL RESIDUAL DISEASE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH INTENSIVE CHEMOTHERAPY

27. S102: LUSPATERCEPT VERSUS EPOETIN ALFA FOR TREATMENT (TX) OF ANEMIA IN ESA-NAIVE LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS (PTS) REQUIRING RBC TRANSFUSIONS: DATA FROM THE PHASE 3 COMMANDS STUDY

29. Freely-chosen positive intergroup imagery causes improved outgroup emotions and encourages increased contact seeking immediately and at follow-up.

30. Chromothripsis in acute myeloid leukemia: biological features and impact on survival

31. A global experience‐sampling method study of well‐being during times of crisis: The CoCo project

32. A global experience-sampling method study of well-being during times of crisis: The CoCo project

33. A global experience-sampling method study of well-being during times of crisis: The CoCo project

34. The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study

35. Supplementary Methods, Tables 1-7, Figures 1-4 from CDKN2A/B Alterations Impair Prognosis in Adult BCR-ABL1–Positive Acute Lymphoblastic Leukemia Patients

41. Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anemia Due to Very Low, Low and Intermediate Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts, Who Had an Unsatisfactory Response to or Are Ineligible for Erythropoietin-Based Therapy: A Retrospective Multicenter Study By Fondazione Italiana Sindromi Mielodisplastiche (FiSiM ETS)

43. Venetoclax Rapidly and Strongly Enhances the Phospholipase C Response to Azacitidine Therapy in Myelodysplastic Syndromes

44. A Chemo-Free Bridge-to-Transplant Strategy with Venetoclax and Azacitidine for NPM1-Mutated Acute Myeloid Leukemia in Molecular Failure

45. Venetoclax and idasanutlin in relapsed/refractory AML: a non-randomized, open-label phase 1b trial

46. Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response

47. The Effects of Teachers’ Motivational Strategies on Learners’ Motivation: A Controlled Investigation of Second Language Acquisition

49. Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia

50. 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial

Catalog

Books, media, physical & digital resources